Currently, three acetylcholinesterase inhibitors (AChEI; i.e., donepezil, galantamine, and rivastigmine) at any stage of AD and memantine (Argueta et al., 2022) for mild to moderate AD have been authorized by FDA (US Food and Drug Administration) as symptomatic pharmacotherapies (Howard et al., 2012; Grossberg et al., 2013; Tisher and Salardini, 2019). The gene discussed is ACHE; the disease is Alzheimer disease.